Serca–VivarRios COVID-19 vaccine: Difference between revisions
No edit summary |
m (page inactive; removing tag) |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Region icon MusgorociaSC}} | {{Region icon MusgorociaSC}} | ||
{{Infobox product | {{Infobox product | ||
| title = Serca–VivarRios COVID-19 vaccine | | title = Serca–VivarRios COVID-19 vaccine | ||
| Line 15: | Line 14: | ||
| last production = | | last production = | ||
| models = Sélvaxin | | models = Sélvaxin | ||
| website = {{url|https://www.selvaxin | | website = {{url|https://www.selvaxin.cs|selvaxin.cs}} | ||
| notes = | | notes = | ||
}} | }} | ||
The '''Serca–VivarRios COVID-19 vaccine''', also sold under the brand name '''Sélvaxin''', is a [[Carloso|Carlosian]] viral vector vaccine against the COVID-19 disease. It was developed as a result of a collaboration between Serca Circuit University and VivarRios Pharmaceuticals. It is injected intramuscularly in two doses, with a 12 week interval. Trials conducted across Carloso and several other countries in [[Musgorocia]] indicate 82.4% efficacy in preventing symptomatic COVID-19, increasing to 91.5% after the second dose. It has the advantage over other vaccines of only needing to be stored at normal refrigerated temperatures (2–8 °C). It is in widespread use across Musgorocia. | The '''Serca–VivarRios COVID-19 vaccine''', also sold under the brand name '''Sélvaxin''', is a [[Carloso|Carlosian]] viral vector vaccine against the COVID-19 disease. It was developed as a result of a collaboration between Serca Circuit University and VivarRios Pharmaceuticals. The vector is a modified {{wpl|Gorilla|gorilla}} {{wpl|Adenoviridae|adenovirus}}. It is injected intramuscularly in two doses, with a 12 week interval. Trials conducted across Carloso and several other countries in [[Musgorocia]] indicate 82.4% efficacy in preventing symptomatic COVID-19, increasing to 91.5% after the second dose. It has the advantage over other vaccines of only needing to be stored at normal refrigerated temperatures (2–8 °C). It is in widespread use across Musgorocia. | ||
It has been the subject of unfounded conspiracy theories and misinformation campaigns supported by enemies of the Carlosian government, including Bourgougia and domestic political opponents. Baseless claims have included a supposed heightened risk of blood clotting in younger people, seizures and lower efficancy among certain age groups. Production of the vaccine has been supported by the Carlosian government and batches are sold at below cost. Starting in March 2021, the Carlosian Armed Forces have begun transporting millions of doses of the Serca–VivarRios vaccine to developing countries as foreign aid. There are plans for VivarRios Pharmaceuticals to enter agreements with domestic suppliers to accelerate production and worldwide access. | It has been the subject of unfounded conspiracy theories and misinformation campaigns supported by enemies of the Carlosian government, including Bourgougia and domestic political opponents. Baseless claims have included a supposed heightened risk of blood clotting in younger people, seizures and lower efficancy among certain age groups. Production of the vaccine has been supported by the Carlosian government and batches are sold at below cost. Starting in March 2021, the Carlosian Armed Forces have begun transporting millions of doses of the Serca–VivarRios vaccine to developing countries as foreign aid. There are plans for VivarRios Pharmaceuticals to enter agreements with domestic suppliers to accelerate production and worldwide access. | ||
The brand name is a play on the Carlosian word for 'salvation' (sélvasion). | |||
==Notes== | ==Notes== | ||
{{Reflist|group=fn}} | {{Reflist|group=fn}} | ||
==See also== | |||
*[[Serca–VivarRios CaBI19 vaccine]] | |||
[[Category:Carloso]] | [[Category:Carloso]] | ||
Latest revision as of 12:15, 31 July 2023
 | |
| Type | Viral vector vaccine |
|---|---|
| Inventor | Serca Circuit University VivarRios Pharmaceuticals |
| Inception | 22 December 2020[fn 1] |
| Manufacturer | VivarRios Pharmaceuticals |
| Available | Approved in Carloso and many other countries |
| Models made | Sélvaxin |
| Website | selvaxin.cs |
The Serca–VivarRios COVID-19 vaccine, also sold under the brand name Sélvaxin, is a Carlosian viral vector vaccine against the COVID-19 disease. It was developed as a result of a collaboration between Serca Circuit University and VivarRios Pharmaceuticals. The vector is a modified gorilla adenovirus. It is injected intramuscularly in two doses, with a 12 week interval. Trials conducted across Carloso and several other countries in Musgorocia indicate 82.4% efficacy in preventing symptomatic COVID-19, increasing to 91.5% after the second dose. It has the advantage over other vaccines of only needing to be stored at normal refrigerated temperatures (2–8 °C). It is in widespread use across Musgorocia.
It has been the subject of unfounded conspiracy theories and misinformation campaigns supported by enemies of the Carlosian government, including Bourgougia and domestic political opponents. Baseless claims have included a supposed heightened risk of blood clotting in younger people, seizures and lower efficancy among certain age groups. Production of the vaccine has been supported by the Carlosian government and batches are sold at below cost. Starting in March 2021, the Carlosian Armed Forces have begun transporting millions of doses of the Serca–VivarRios vaccine to developing countries as foreign aid. There are plans for VivarRios Pharmaceuticals to enter agreements with domestic suppliers to accelerate production and worldwide access.
The brand name is a play on the Carlosian word for 'salvation' (sélvasion).
Notes
- ↑ The date the rollout of the Serca–VivarRios COVID-19 vaccine began in Carloso.